Beyond Billion-Dollar Bets: How Affibody Might Solve Radioligand Therapy's Greatest Challenges

The radioligand therapy market will be worth $42 billion by 2032. However, beneath the headline-grabbing acquisitions lies a complex web of technical and commercial challenges that threaten to limit patient access to these revolutionary cancer treatments. The path to successful radioligand development is fraught with obstacles, from the "melting ice cube" logistics of short-lived radioisotopes to the renal toxicity pitfalls that plague small-molecule approaches.

In this episode of BioBiz Buzz, your host Mike Ward sits down with David Bejker, CEO of Swedish biotech Affibody, to explore how engineered protein platforms are systematically addressing the industry's most pressing challenges. With over 20 years of radioligand development experience and more than 200 patients dosed, Affibody has developed a unique solution: engineered proteins 25 times smaller than traditional antibodies that deliver targeted radiation with unprecedented precision while avoiding the toxicity issues that have historically limited therapeutic efficacy.

Click here to read more